Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ADC Therapeutics SA

Healthcare US ADCT

1.375USD
-1.705(55.36%)

Last update at 2026-06-04T18:17:00Z

Day Range

1.331.56
LowHigh

52 Week Range

1.234.98
LowHigh

Fundamentals

  • Previous Close 3.08
  • Market Cap522.75M
  • Volume9213416
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-105.39000M
  • Revenue TTM81.36M
  • Revenue Per Share TTM0.64
  • Gross Profit TTM -26.16200M
  • Diluted EPS TTM-1.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Income before tax -142.78000M -157.68000M -195.41900M -154.66100M -154.66100M
Minority interest - - - - -
Net income -142.62300M -157.84600M -240.05300M -155.80000M -155.80000M
Selling general administrative 36.56M 64.47M 48.42M 141.06M 141.06M
Selling and marketing expenses 43.37M 21.44M 57.46M 69.05M 69.05M
Gross profit 73.68M 64.89M 67.03M 205.33M 205.33M
Reconciled depreciation 1.88M 3.28M 2.83M 2.33M 2.33M
Ebit -108.37900M -105.92500M -150.02900M -110.44300M -123.62700M
Ebitda -106.50300M -102.64900M -146.76200M -108.05500M -98.83500M
Depreciation and amortization 1.88M 3.28M 3.27M 2.39M 24.79M
Non operating income net other - - - - -
Operating income -108.37900M -130.65400M -165.98600M -123.62700M -123.62700M
Other operating expenses 189.74M 201.49M 235.54M 333.54M 333.54M
Interest expense 51.63M 50.21M 46.33M 36.92M 36.92M
Tax provision 1.01M 0.17M -2.99100M 1.14M 1.14M
Interest income 8.81M 12.27M 6.62M 17.97M 17.97M
Net interest income -42.82300M -37.93900M -39.57700M -18.95400M -18.95400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.15700M 0.17M 39.11M 1.14M 1.14M
Total revenue 81.36M 70.84M 69.56M 209.91M 209.91M
Total operating expenses 182.06M 195.54M 233.01M 328.96M 328.96M
Cost of revenue 7.67M 5.95M 2.53M 4.58M 4.58M
Total other income expense net -34.40100M -27.02600M -29.43300M -33.55700M -31.03400M
Discontinued operations - - - - -
Net income from continuing ops -142.62300M -157.84600M -178.50700M -155.80000M -155.80000M
Net income applicable to common shares - - - -155.80000M -155.80000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Total assets 323.15M 321.98M 354.78M 529.17M 529.17M
Intangible assets - - - 14.36M 14.36M
Earning assets - - - - -
Other current assets 11.70M 17.82M 16.33M 23.50M 28.04M
Total liab 508.98M 524.62M 503.03M 440.44M 440.44M
Total stockholder equity -185.83400M -202.64200M -148.24900M 88.73M 88.73M
Deferred long term liab - - - 0.95M 0.95M
Other current liab 57.99M 61.07M 49.17M 68.49M 73.03M
Common stock 11.08M 8.43M 7.31M 7.31M 7.31M
Capital stock 11.08M 8.43M 7.31M 7.31M 7.31M
Retained earnings -1635.94100M -1493.31800M -1335.47200M -1080.68500M -1080.68500M
Other liab - - - 25.33M 25.33M
Good will - - - - -
Other assets - - 0.00000M 28.61M 28.61M
Cash 261.34M 250.87M 278.60M 326.44M 326.44M
Cash and equivalents - - - - -
Total current liabilities 70.16M 80.47M 67.67M 98.96M 98.96M
Current deferred revenue - - - - -
Net debt 177.67M -127.86900M -154.22100M -209.06600M -209.06600M
Short term debt 3.00M 1.37M 2.93M 1.10M 13.57M
Short long term debt 3.00M - - 12.47M 12.47M
Short long term debt total 439.01M 123.00M 124.38M 117.38M 117.38M
Other stockholder equity 1439.54M 1283.67M 1180.00M 1165.73M 1006.77M
Property plant equipment - - - 9.98M 9.98M
Total current assets 306.33M 307.39M 336.29M 446.01M 446.01M
Long term investments - 0.00000M 1.65M 31.15M 31.15M
Net tangible assets - - - 75.32M 75.32M
Short term investments - - - - -
Net receivables 29.12M 20.32M 25.18M 72.97M 77.71M
Long term debt 112.45M 113.63M 112.73M 97.24M 97.24M
Inventory 4.18M 18.39M 16.18M 18.56M 18.56M
Accounts payable 9.18M 18.03M 15.57M 12.35M 12.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.51700M -1.42100M -0.09300M 155.33M 155.33M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 15.52M 1.16M 0.71M 0.90M 0.90M
Deferred long term asset charges - - - - -
Non current assets total 16.82M 14.59M 18.49M 83.15M 83.15M
Capital lease obligations 1.57M 9.37M 11.65M 7.66M 7.66M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Investments - -0.86700M -2.39900M -2.50800M -2.50800M
Change to liabilities - - - 0.31M 0.31M
Total cashflows from investing activities 0.40M -0.86700M - -2.50800M -2.50800M
Net borrowings - - - -6.50200M -6.50200M
Total cash from financing activities 150.94M 97.05M 73.88M -0.59300M -0.59300M
Change to operating activities - - - 16.55M 16.55M
Net income -142.62300M -157.84600M -240.05300M -155.80000M -155.80000M
Change in cash 10.47M -27.73100M -47.84300M -140.10300M -140.10300M
Begin period cash flow 250.87M 278.60M 326.44M 466.54M 466.54M
End period cash flow 261.34M 250.87M 278.60M 326.44M 326.44M
Total cash from operating activities -141.17400M -123.83500M -118.68600M -136.79400M -136.79400M
Issuance of capital stock 86.28M 60.51M -0.06200M 6.13M 6.13M
Depreciation 1.88M 3.28M 3.27M 2.33M 2.33M
Other cashflows from investing activities - - - -0.21000M -0.21000M
Dividends paid - - - - -
Change to inventory -2.38100M -3.72800M 1.61M -8.96400M -8.96400M
Change to account receivables -8.78900M 4.77M 47.79M -42.75300M -42.75300M
Sale purchase of stock - - - -0.22100M -0.22100M
Other cashflows from financing activities -1.51400M 36.55M 73.88M -4.32000M -5.49100M
Change to netincome - - - 49.69M 49.69M
Capital expenditures 0.26M 0.87M 3.22M 2.30M 2.30M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -25.35500M 3.83M 44.27M -33.01000M -33.01000M
Stock based compensation 6.91M 6.57M 13.49M 49.32M 49.32M
Other non cash items 18.02M 20.34M 23.23M 1.07M 1.07M
Free cash flow -141.43800M -124.70200M -121.90200M -139.09200M -139.09200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADCT
ADC Therapeutics SA		 -1.705 55.36% 1.38 - - 6.43 3.42 4.87 -1.4269
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADC Therapeutics SA

BiopOle, Epalinges, Switzerland, 1066

Key Executives

Name Title Year Born
Dr. Ameet Mallik M.B.A., M.S. CEO & Director 1972
Dr. Christopher J. Martin DPHIL, Ph.D. Co-Founder & Non-Exec. Director 1959
Ms. Jennifer Creel Chief Financial Officer 1971
Dr. Michael Mulkerrin Ph.D. Chief Technical Operations Officer NA
Dr. Patrick van Berkel Ph.D. Chief Scientific Officer 1968
Amanda Hamilton Investor Relations Officer NA
Ms. Susan Romanus Chief Compliance & Quality Officer 1965
Mr. Peter J. Graham Esq. Chief Legal Officer 1967
Ms. Kimberly Pope Sr. VP & Chief People Officer 1966
Dr. Joseph Camardo Ph.D. Chief Medical Officer 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions